Monica Stonehill is a Managing Editor at Healio. With a background in medical journalism since 2015, she specializes in various medical fields including gastroenterology, orthopedics, nephrology, and rheumatology. Stonehill's work has been featured in Healio, showcasing her commitment to delivering insightful medical content.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Monica Stonehill's coverage centers on healthcare and scientific topics, particularly in the fields of gastroenterology and hepatology. She frequently cites data to support her articles and relies on exclusive information.
Given Monica's focus, she would likely be interested in receiving pitches from experts who can provide insightful commentary or analysis about medical advances, liver diseases, digestive system issues, and developments within the fields of gastroenterology and hepatology. Sources with access to exclusive information or data-driven insights related to these areas may also capture her attention.
Monica appears not to have a specific geographic focus but instead focuses on global advancements in healthcare and scientific research within the specified fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Monica Stonehill, Heather Biele, Monica Avila
Video Player is loading. Play Video Replay Skip Backward Skip Forward Unmute Current Time Duration
By: Monica Avila, Monica Stonehill
In this video, Monica Avila, MD, MPH, discusses results from the RAMP-201 trial of avutometinib and defactinib, which showed potential to expand its use to include patients with KRAS wild-type low-grade serous ovarian cancer.In May 2025, the FDA granted accelerated approval to avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem Inc.) for KRAS-mutated recurrent low-grade serous ovarian
By: Monica Avila, Monica Stonehill
In this video, Monica Avila, MD, MPH, discusses results that showed letrozole alone was not noninferior to chemotherapy followed by letrozole for low-grade serous ovarian, fallopian tube or peritoneal carcinoma.In the phase 3, NRG-GY019 noninferiority trial, presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, patients with stage II to IV disease who underwent
By: Monica Stonehill, Noah Merin
VIDEO: Multidisciplinary care services help maintain quality of life in patients with AML
By: Noah Merin, Monica Stonehill
VIDEO: Participation in clinical trials may curb disparities in acute myeloid leukemia
By: Noah Merin, Monica Stonehill
Transcript Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.
By: Noah Merin, Monica Stonehill
VIDEO: Research underway to assess combination therapy regimens in acute myeloid leukemia
By: Monica Stonehill, Noah Merin
VIDEO: AI an ‘incredible' tool to enhance physician-patient discussions on AML diagnosis
AML therapy regimens offer flexibility to fit patient needs
By: Noah Merin, Monica Stonehill
Minimal residual disease tests may ‘better match’ patients with care in AML
